Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Celltrion's MabThera cleared by EC for autoimmune diseases and cancer

The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.

Belgian CAR-T biotech enrols first blood cancer patient in new trial

Celyad SA has enrolled the first multiple myeloma patient in a safety and tolerability trial of its CAR-T therapy.


Raging bull' - Vaccines don’t cause autism and saying otherwise costs lives

Vaccines do not cause autism and people who say otherwise are wrong.

CRB sister Discovery launches second antibody catalogue

Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.

Sanofi hires Selexis SA for three cell line development deals

Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.

CellGenix GmbH starts work on cell therapy regent facility expansion

CellGenix GmbH has started expanding its cell and gene therapy reagents facility in Freiburg, Germany citing the progression of customer projects into clinical development and commercial launch.

Promotional Features

Key Industry Events


Access all events listing

Our events, Shows & Conferences...